Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Discovery

Octarine Bio

1 Drug Candidate

Octarine Bio is a Danish synthetic biology company producing psilocybin and other neuroactive compounds via proprietary yeast fermentation. Founded in Copenhagen, the company raised $11M from 13 investors including DSM-Firmenich and has partnered with Clerkenwell Health to supply GMP psilocybin for clinical trials. Octarine Bio's platform is based on engineering yeast to express the biosynthetic pathway for psilocybin and related alkaloids.

Drug Pipeline

1

Biosynthetic psilocybin

Psilocybin
Discovery

GMP psilocybin produced via engineered yeast fermentation; clinical supply partnership with Clerkenwell Health.

Quick Facts

Type
Private Biotech
Lead Stage
Discovery
Website
Visit